



BRYAN, GARNIER & CO

DAILY EQUITY RESEARCH UPDATE
Wake-up Call

Dow Jones: 25,806.63 (10.63% ytd) | CAC40: 5297.52 (11.98% ytd) | Stoxx 600: 375.641(11.25% ytd)

6th March 2019

Please find our Research on Bloomberg BRYG <GO>

CARLSBERG | NEUTRAL | DKK860 vs. DKK760

- Model maintenance post results
- Model maintenance - 2019 operating profit forecasts increased by 3%
- A step up in organic revenue growth
- Management remuneration policy could lead to less profit and more top line growth
- Results and guidance were in line with consensus

CAMPARI | NEUTRAL | EUR7.5

- Q4 organic sales growth miss
- Slower organic sales growth in Q4
- Full year EBIT margin up 50bp in organic terms
- Emerging markets expected to bounce back in 2019
- Neutral recommendation reiterated due to valuation

DIALOG SEMICONDUCTOR | NEUTRAL | EUR24.5

- Good Q4 results with Q1 revenue guidance slightly below estimates
- Dialog reported Q4 2018 EPS well above expectations
- Shy performance across the board but AMS profitability improved
- Q1 2019 revenue guidance 3% below expectations

DBV TECHNOLOGIES | BUY | EUR46

- Reorganisation in progress
- Significant reduction in cash burn in Q4 2018
- Changes in leadership team but no cost saving plan
- Recent publications from Aimmune
- DBV is heading towards a BLA filing in Q3

AB INBEV | BUY | EUR 100 (report out today)

- Battle for the Middle Kingdom
- Asia Pacific is the largest beer region in the world accounting for 38% of global beer volumes and is expected to account for over 60% of beer volume and revenue growth over the next twenty years. China alone will be 30% of global growth and India another 10%. Whereas India is an organic growth story, China already is the world's largest beer market (26% of global volumes) and is in the process of consolidating. AB InBev built a 14% volume market share in the Asia Pacific region including 15% in China (26% value share) and 21% in India. While they continue to grow organically in India, taking part in the consolidation process in China should be an important priority. Indeed, one of the pillars of AB InBev's superior margin profile is to have large market shares in big beer countries (e.g. USA and Brazil).

Upcoming BG events :

Date	
7th-Mar	AB inBev Genève Roadshow with IR
14th-Mar/ 15th-Mar	4th Annual Technology Conference
3rd-Apr	CAPGEMINI Luxembourg roadshow with CFO / IR
30th-Apr	BIOCARTIS London roadshow with CEO/IR

Recent reports :

Date	
6th-Mar	AB INBEV Battle for the Middle Kingdom
19th-Feb	SUMMIT THERAPEUTICS Superiority: The Right Drug for the Right Bug
12th-Feb	TRANSGENE The Platform Approach Is Worth Another Look
8th-Feb	CARBIOUS Plastic is fantastic!
8th-Feb	CARBIOUS Le plastique c'est fantastique !
8th-Feb	IANTHUS Blossom in the USA

Q1 2019 Top Picks

- SANOFI (Buy, FV EUR94)
- NOVARTIS (Buy, FV CHF96)
- ROCHE HOLDING (Buy, FV CHF315)
- GALAPAGOS (Buy, FV EUR125)

CARLSBERG

Consumer, Brands & Retail
| Brewers

6th March 2019

NEUTRAL

Fair Value DKK860 vs. DKK760
(+6%)
Share price DKK814.00
EPS 3Y Cagr 12.1%

Model maintenance post results

Model maintenance - 2019 operating profit forecasts increased by 3%

We have updated our forecasts for Carlsberg and have taken a slightly more aggressive view on 2019, increasing our revenue forecast by about 1.5% for 2019 given no further negative impact of the rouble and a step up in organic growth to 3.0% (which is slower than the 6.5% of 2018 given the high comps on weather and the world cup football). Nevertheless, Q4 organic sales of 3.2% were clean and not impacted by any external factors except for easy comps in India. We increase 2019 operating profit by about 3% driven by the clear commitment and proven improvement in operational efficiency in Western Europe and signs of a strong premiumisation trend in beer in Asia Pacific. The announced share buyback of DKK4.5bn should have a positive impact on EPS and FV of about 3%. As a result of the combined impact of increased earnings outlook, share buy-back and elapsed time since our last update, we increase our fair value for the shares by 13% to DKK860 from DKK760.

A step up in organic revenue growth

Following on from the strong clean delivery in Q4 with group organic revenue growth of 3.2% and spread across all regions with Western Europe up 2.8%, Eastern Europe 11% and Asia Pacific 14%, it seems that Carlsberg's reinvestment strategy is working. Before 2018 organic revenue growth of 6.5%, the company averaged 1.5% over the five previous years. While the 6.5% might be explained by a convergence of favourable weather and the World Cup football tournament, the 3.2% of Q4 looks likely to be the new norm.

Management remuneration policy could lead to less profit and more top line growth

Management's bonuses are linked, 25% each with total shareholder return, organic sales growth, EPS growth and growth in ROIC. 100% vests for upper-quartile performance, 4.5% organic sales growth, 9% organic EPS growth, 10% ROIC in 2021 (after achieving 8.1% in 2018). Except for the share price performance, which management does not really have an impact on (although we notice that Tsingtao is in the base and not CR Beer), it will be interesting to see how these different elements play out. In our forecasts, we have organic sales growth of 3-3.5% in the years ahead but, thanks to the share buyback, 13% EPS growth. The board seems to be steering to more reinvestment in top-line growth and less profit growth.

Results and guidance were in line with consensus

Earlier, Carlsberg delivered for 2018 revenue of DKK62.5bn which was fractionally ahead of (0.6%) of consensus that stood at DKK62.1bn. Reported EBIT of DKK9,329m was very much in line with consensus at DKK9,335m. Adjusted net profit of DKK5,359m was in line with the DKK5,338m that was expected. For 2019, management expects mid-single-digit percentage organic growth in operating profit and no foreign exchange impact. Consensus is expecting 5% organic/reported growth.

Market Data

Bloomberg / Reuters	CARLB DC/CARCb.CO
Market Cap.	DKK123,305m
E.V.	DKK174,871m
Free Float	69.7
Avg. Daily volume (6m)	247.3
12m high / low	814.0 / 682.8
Ytd Perf.	17.5%

DKKM	12/18	12/19e	12/20e	12/21e
Sales	62,503	64,924	66,864	68,905
% Change		3.9%	3.0%	3.1%
EBITDA	13,222	14,019	14,769	15,571
% Change		6.0%	5.3%	5.4%
EBIT	9,158	9,955	10,673	11,436
% Change		8.7%	7.2%	7.2%
Net Income	5,359	5,912	6,393	6,903
% Change		10.3%	8.1%	8.0%
ROE	0.12	0.14	0.15	0.17

	12/18	12/19e	12/20e	12/21e
EV/Sales	2.8x	2.7x	2.6x	2.5x
EV/EBITDA	13.2x	12.5x	11.8x	11.2x
EV/EBIT	19.1x	17.6x	16.4x	15.2x
EPS	35.00	39.43	44.11	49.33
% change		12.7%	11.9%	11.8%
P/E	23.3x	20.6x	18.5x	16.5x
Div Yield	1.6%	1.8%	2.0%	2.2%

Next Catalyst: 2 May 2017: Q1 trading statement

Last rating Change:

2018-6-25, Good weather and World Cup
Last FV Change:
2018-11-1, Strong Q3 was anticipated

Last Reports:

2019-2-6, Strong 2018 results across the board

Nikolaas Faes

33(0) 6 11 12 44 44
nfaes@bryangarnier.com

[Click here to download](#)

CARLSBERG

NEUTRAL

Fair Value	DKK860 vs. DKK760 (+6%)
Share price	DKK814.00
Market Cap.	DKK123,305m
EPS 3Y	12.1%
CAGR	

Simplified Profit & Loss Account (DKKm)	2017	2018	2019e	2020e	2021e
Revenues	61,808	62,503	64,924	66,864	68,905
Change (%)	-1.3%	1.1%	3.9%	3.0%	3.1%
EBITDA	13,198	13,222	14,019	14,769	15,571
EBIT	8,617	9,158	9,955	10,673	11,436
Change (%)	11.3%	6.3%	8.7%	7.2%	7.2%
Financial results	-788	-722	-780	-784	-794
Pre-Tax profits	7,829	8,436	9,175	9,889	10,642
Exceptionals	-4,578	-47	-129	-126	-124
Tax	-1,458	-2,386	-2,496	-2,690	-2,894
Profits from associates	262	130	150	172	198
Minority interests	-806	-824	-882	-943	-1,009
Net profit	1,249	5,309	5,817	6,301	6,813
Restated net profit	4,925	5,359	5,912	6,393	6,903
Change (%)	26.9%	8.8%	10.3%	8.1%	8.0%
Cash flow Statement (DKKm)					
Operating cash flows	12,940	13,316	13,890	14,643	15,448
Change in working capital	1,236	1,960	571	458	482
Capex, net	-3,838	-3,955	-4,545	-4,680	-4,823
Financial investments, net	520	-2,462	0	0	0
Dividends	-2,421	-2,674	-2,965	-3,204	-3,458
Other	-2,436	-2,746	-7,260	-7,431	-7,619
Net debt					
Free Cash flow	7,996	8,083	6,640	6,946	7,418
Balance Sheet (DKKm)					
Shareholders' funds	46,930	45,302	43,655	42,251	41,106
+Net debt	20,727	18,394	18,453	18,608	19,009
Fixed assets	114,251	117,700	118,298	118,899	119,624
+ Other	6,881	7,352	7,352	7,352	7,352
=Capital employed	92,392	85,718	84,510	84,004	83,984
Total Balance sheet	114,251	117,700	118,298	118,899	119,624
Financial Ratios					
Operating margin	13.9%	14.7%	15.3%	16.0%	16.6%
Tax rate	29.0%	28.4%	27.0%	27.0%	27.0%
Net margin	8.0%	8.6%	9.1%	9.6%	10.0%
ROE (after tax)	10.5%	11.8%	13.5%	15.1%	16.8%
ROCE (after tax)	6.6%	7.6%	8.6%	9.3%	9.9%
Gearing	49%	44%	45%	46%	47%
Pay out ratio	195.8%	51.9%	51.8%	51.7%	51.7%
Number of shares, diluted	153	153	150	145	140
Data per Share (DKK)					
EPS	8.2	34.7	38.8	43.5	48.7
Restated EPS	32.2	35.0	39.4	44.1	49.3
Change(%)	26.6%	8.6%	12.7%	11.9%	11.8%
BV	308	297	296	297	299
Operating cash flows	85	87	93	101	110
FCF	52	53	44	48	53
Net dividend	11.52	12.96	14.48	16.20	18.11

Source: Company Data; Bryan, Garnier & Co ests.

CAMPARI

Consumer, Brands & Retail
| Spirits

6th March 2019

NEUTRAL

Fair Value EUR7.5(-5%)
Share price EUR7.91
EPS 3Y Cagr 8.9%

Q4 organic sales growth miss

Slower organic sales growth in Q4

Reported sales over the quarter declined 2.1% to EUR511.1m (consensus: EUR510m) due to 1/ FX headwinds (-1.4%) and 2/ a negative scope effect (-2.8%) related to the end of distribution contracts with Brown-Forman in Italy and the disposal of Lemonsoda. In organic terms, Q4 sales only increased 2.1%, well below expectations (our estimate: +4.5% and consensus: +5%). The deceleration (we warned of in our preview dated 21st January) vs Q3 (+8.9%) was significant and stemmed from 1/ Argentina (1% of sales) due to a faster volume decline in tough macro conditions and the exclusion of price effect because of IAS29 (Argentina had a -80bp impact on organic sales growth in Q4), 2/ Germany (10% of sales) and South Africa (1% of sales) where the comparison base was unfavourable and 3/ a slowdown at Aperol (+18.7% in Q4 post +42.9% in Q3) due to lower activations in Q4 than during the summer season, which was penalizing for markets such as the UK, France, Spain and the US (Italy, Austria, Germany and Switzerland are widely deseasonalized).

Full year EBIT margin up 50bp in organic terms

2018 EBIT reached EUR378.8m (consensus: EUR378m), pointing to a margin of 22.1%, up 40bp in reported terms. Organically, the increase reached 50bp, implying a rise of 70bp in Q4 as the positive sales mix prompted by the outperformance of global/regional priorities in developed markets offset rising agave prices, AP and structure costs.

Emerging markets expected to bounce back in 2019

Organic sales growth should accelerate this year on the back of a recovery by 1/ Russia, expected to be up high single/low double digit (-11.4% in 2018), 2/ Argentina, expected to be up mid to high single digit (-32.4% in 2018) and 3/ Brazil, expected to be up around 5% (-2.8% in 2018). Our estimate is now for 6% vs +5.2% previously (+5.3% in 2018). This should have a negative mix impact as these countries are less profitable. We expect an organic EBIT margin expansion of 40bp in 2019 (after +50bp in 2018). In reported terms, our forecasts are broadly unchanged due to more penalizing FX and scope effects than anticipated (-EUR21m on sales and -EUR5/6m on EBIT).

Neutral recommendation reiterated due to valuation

The steep slowdown in organic sales growth in Q4 was a big disappointment. This was partly explained by technical factors, we continue to see the underlying business as solid. The stock was down 6% yesterday, which appears perfectly logical given its strong performance over the last three months (+8%). We rate the stock Neutral due to valuation. At yesterday's share price, it trades at a 2019e EV/EBIT of 24.7x, globally in line with Rémy Cointreau, while Campari (contrary to RCO) is not positioned in a category with very high barriers to entry and does not have highly valuable eau-de-vie inventories.

Market Data

Bloomberg / Reuters	CPR IM/CPR.MI
Market Cap.	EUR9,188m
E.V.	EUR10,815m
Free Float	49
Avg. Daily volume (6m)	2,268
12m high / low	8.5 / 5.9
Ytd Perf.	7.1%

EURM	12/18	12/19e	12/20e	12/21e
Sales	1,712	1,795	1,903	2,019
% Change		4.9%	6.0%	6.1%
EBITDA	432.6	459.4	494.7	532.6
% Change		6.2%	7.7%	7.7%
EBIT	378.8	403.8	435.7	470.0
% Change		6.6%	7.9%	7.9%
Net Income	249.3	271.7	300.1	330.5
% Change		9.0%	10.5%	10.1%
ROE	0.14	0.12	0.11	0.12

	12/18	12/19e	12/20e	12/21e
EV/Sales	5.9x	5.6x	5.2x	4.8x
EV/EBITDA	23.2x	21.7x	20.0x	18.4x
EV/EBIT	26.5x	24.7x	22.7x	20.8x
EPS	0.22	0.23	0.26	0.28
% change		6.3%	10.5%	10.1%
P/E	36.0x	33.8x	30.6x	27.8x
Div Yield	0.6%	0.7%	0.7%	0.7%

Next Catalyst: Q1 2019 sales on 7th May

Last rating Change:

2018-7-10, *Downgraded to Neutral on valuation grounds*

Last FV Change:

2019-1-21, *An expected soft end to the year*

Last Reports:

2019-1-21, *An expected soft end to the year*

Virginie Roumage, CFA
33(0) 1.56.68.75.22
vroumage@bryangarnier.com

[Click here to download](#)

DIALOG SEMICONDUCTOR

Technology
| Semiconductors

6th March 2019

NEUTRAL

Fair Value EUR24.5 (-7%)
Share price EUR26.42
EPS 3Y Cagr -16.2%

Good Q4 results with Q1 revenue guidance slightly below estimates

Dialog reported Q4 2018 EPS well above expectations

For Q4 2018, Dialog reported sales of USD431.0m, up 12.4% seq. (-7.0% yoy) in line with the preliminary figures published in January and at the low-end of the previous guidance calling for revenue of between USD430m and USD470m. The profitability keeps improving and was above the consensus with underlying gross margin that came out at 48.7%, about 130bp above the street's forecast for GM at 47.4% (BG ests. 47.5%). Underlying EBIT was also 6.1% above expectations at USD103.4m (cons. USD98m/BG ests. USD106m). As such, underlying diluted EPS came out at USD1.06, above consensus estimates at USD1.00 (BG ests. USD1.10).

Shy performance across the board but AMS profitability improved

Dialog registered 4Q18 revenues of USD327m (+19.6% seq, -13.3% yoy) in mobile systems, above the consensus for USD318m. As we expected, note that profitability in this segment decreased from 31.3% in Q4 2017 to 29.1% highlighting a lower contribution from the main PMIC business with Apple in the total mix. The Advanced Mixed Signal business, which is the company's fastest growing business this year thanks to the acquisition of Silego declined by -8.5% seq. (+42.3% yoy) to USD57m compared with the street's estimate of USD62m. The segment includes revenue from the power conversion business which was up 12.8% compared with last year and continuing growth in Silego, which registered USD30m in revenue (+5.4% seq). The segment's operating margin improved from 3.6% in Q4 2017 to 11.2% in Q4 2018. The Connectivity business was down sequentially by 4.1% to USD39m (+6.1% yoy) compared with the consensus at USD41m while the Automotive and Industrial segment was down by -8.8% seq. to USD7m (-14.9% yoy) compared with the consensus at USD9m.

Q1 2019 revenue guidance 3% below expectations

Dialog sees Q1 2019 sales in the range of USD270m and USD310m, i.e. a sequential decline of 32.7% to about USD290m at mid-range. This is 3% below the consensus forecast for revenue of USD300m and in line with our estimates at USD290m. Gross margin guidance for FY 2019 to be broadly in line with FY 2018 (at 48.3%) compares with the consensus forecast for GM of 47.2%. Based on our estimates, Dialog's shares are trading on 12m fwd P/E ratios of 10.5x.

Market Data

Bloomberg / Reuters	DLG GR/DLGS.DE
Market Cap.	EUR2,018m
E.V.	EUR1,540m
Free Float	70.3
Avg. Daily volume (6m)	4.90
12m high / low	27.0 / 12.7
Ytd Perf.	17.3%

USDM	12/17	12/18e	12/19e	12/20e
Sales	1,353	1,442	1,355	804.1
% Change		6.6%	-6.0%	-40.7%
EBITDA	315.8	343.3	323.4	209.4
% Change		8.7%	-5.8%	-35.3%
EBIT	187.0	210.0	200.5	107.8
% Change		12.3%	-4.5%	-46.3%
Net Income	228.0	228.4	212.3	120.3
% Change		0.2%	-7.1%	-43.3%
ROE	0.13	0.10	0.11	0.05

	12/17	12/18e	12/19e	12/20e
EV/Sales	1.1x	1.0x	0.8x	1.1x
EV/EBITDA	4.9x	4.1x	3.3x	4.4x
EV/EBIT	8.3x	6.6x	5.3x	8.5x
EPS	2.92	2.93	3.03	1.72
% change		0.4%	3.3%	-43.3%
P/E	10.2x	10.2x	9.9x	17.4x
Div Yield	NM	NM	NM	NM

Next Catalyst:

Today, 9.30am: Q4 2018 conference call

15 March 2019: Dialog at BG TMT conference

Last rating Change:

2018-11-2, CMD feedback: more visibility on Dialog's LT profile

Last FV Change:

2018-11-2, CMD feedback: more visibility on Dialog's LT profile

Last Reports:

2019-1-14, Dialog reports preliminary revenue at the low end of the guidance

Frédéric Yoboué

33(0) 1 56 68 75 54

fyoboue@bryangarnier.com

[Click here to download](#)

DBV TECHNOLOGIES

Healthcare
| Biotech

6th March 2019

BUY

Fair Value EUR46(+237%)
Share price EUR17.45
EPS 3Y Cagr NM

Reorganisation in progress

Significant reduction in cash burn in Q4 2018

Regarding FY2018 results at DBV, the key item for us is cash position and cash burn. Interestingly, the latter was down sharply in Q4 2018 at only EUR15.1m compared with EUR32m in Q2 2018 and EUR48m in Q3 2018. At the end of 2018, DBV had EUR122.8m in cash and if Q4 2018 cash burn is maintained the group has enough cash until end 2020. However the company is stating that it is financed until end 2019 as investment will be needed to support the future launch of Viaskin Peanut. Sales & Marketing expenses increased to EUR32.2m in 2018 (from EUR15.8m in 2017) reflecting efforts for the potential launch of Viaskin Peanut in the US. As such, we may think the company has enough resources to launch the drug, but not so sure.

Changes in leadership team but no cost saving plan

After the failure of Viaskin Peanut filing in the US, DBV announces some important changes in its top management structure. Yesterday, Pierre-Henri Benhamou left the Board to be replaced by Michel de Rosen as Chairman. Today DBV has announced the departure of the COO (in charge of the regulatory, product development and commercial operations), and of the Chief Development Officer in charge of regulatory. However, no cost saving plan has been announced but with the cash burn reduction seen in Q4 2018 it is probably already in place.

Recent publications from Aimmune

At the AAAAI meeting last week, AIMT presented new data from the PALISADE phase III trial showing that after the 6 month dose escalation, there was a 70% risk reduction to peanut allergic reaction due to accidental exposure vs placebo. These results are slightly lower than those obtained with Viaskin Peanut showing a relative risk reduction of 74.7% to 96.6% after 12 months of treatment (Remington et al.). Turning to the timing for the review of AR-101 by the FDA, the latter should decide whether to accept the filing by the end of March. Considering that AR-101 is a non-PDUFA product, discussions with the FDA are ongoing on whether AR-101, which has BTM by the FDA will be reviewed under expedited timelines.

DBV is heading towards a BLA filing in Q3

DBV reiterated the timeline for re-filing of Viaskin Peanuts' BLA with the FDA in Q3 2019. In light of the work that needs to be done to complete the filing (SOPs primarily), we remain confident in the group's ability to meet with this timeline. Our assumptions, adjusted for the withdrawal of the initial BLA in December 2018, assumed a re-filing around mid-2019. Meanwhile, we would expect DBV to continue to raise awareness on peanut allergy and its effort to bring Viaskin Peanut to the market. This should be eased by the recent publication of the PEPITES phase III results in the JAMA.

Market Data

Bloomberg / Reuters	DBV FP/DBV.PA
Market Cap.	EUR526m
E.V.	EUR320m
Free Float	55.3
Avg. Daily volume (6m)	311.5
12m high / low	42.6 / 7.7
Ytd Perf.	64.5%

EURM	12/17	12/18e	12/19e	12/20e
Sales	7.5	8.1	9.4	66.0
% Change		8.5%	15.8%	
EBITDA	-153.2	-204.0	-245.7	-163.2
% Change		-33.2%	-20.4%	33.6%
EBIT	-154.2	-205.0	-245.9	-164.2
% Change		-33.0%	-19.9%	33.2%
Net Income	-154.2	-205.0	-245.9	-164.2
% Change		-33.0%	-19.9%	33.2%
ROE	-1.74	-0.79	-1.16	-3.38

	12/17	12/18e	12/19e	12/20e
EV/Sales	58.1x	34.0x	35.7x	7.8x
EV/EBITDA	NS	NS	NS	NS
EV/EBIT	NS	NS	NS	NS
EPS	-6.31	-4.09	-4.90	-3.27
% change		35.1%	-19.9%	33.2%
P/E	NS	NS	NS	NS
Div Yield	NM	NM	NM	NM

Next Catalyst: Q3 2019: Viaskin Peanut BLA filing

Last FV Change:

2018-12-20, Few details on resubmission timeline following BLA withdrawal

Last Reports:

2019-2-14, Building-up a newsflow until BLA resubmission expected in Q3 19

Hugo Solvet

33(0) 1 56 68 75 57

hsolvvet@bryangarnier.com

[Click here to download](#)

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 55.1%

NEUTRAL ratings 38.1%

SELL ratings 6.8%

Bryan Garnier Research Team

Healthcare	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Pharmaceuticals	Jean-Jacques Le Fur, PharmD	33 (0) 1 70 36 57 45	jjlefur@bryangarnier.com
	Biotech	Gary Waanders, PhD	44 207 332 25 45	gwaanders@bryangarnier.com
	Medtech / Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
	Biotech / Medtech	Victor Floc'h	33 (0) 1 70 36 57 01	vfloch@bryangarnier.com
	Biotech	Ross Blair, MbChB	44 207 332 25 05	rblair@bryangarnier.com
Technology	Payments, Security & Video games	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom & Media	Thomas Coudry	33 (0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Lodging & Business services	Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
	Innovative materials & Construction	Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
	Insurance & Fintech	Olivier Pauchaut <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
	Software & IT services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
	Industrial software	David Vignon	33 (0) 1 56 68 75 92	dvignon@bryangarnier.com
	Semiconductors	Frédéric Yoboué	33 (0) 1 56 68 75 64	fyoboue@bryangarnier.com
Consumer, Brands & Retail	Beverages & Cannabis	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retail & e-commerce	Clément Genelot	33 (0) 1 56 68 75 60	cgenelot@bryangarnier.com
	Luxury & Cosmetics	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	HPC & e-commerce	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
Corporate Event Manager	Julie Montel	33 (0) 1 56 68 75 46	jmontel@bryangarnier.com	
Market Data & Information Systems Manager	Eric Monnier	33 (0) 1 56 68 75 63	emonnier@bryangarnier.com	

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

Nikolaas FaesLondon Beaufort House 15 St. Botolph Street London EC3A 7BB United Kingdom +44 207 332 2500	Paris Bryan, Garnier & Co Ltd 26 Avenue des Champs- Elysées 75008 Paris France +33 1 56 68 75 20	Munich Bryan, Garnier & Co. GmbH Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11	Zurich Bryan, Garnier & Co Theaterstrasse 4 8001 Zurich Switzerland +41 44 991 3300	New York Bryan Garnier Securities 750 Lexington Avenue 16th floor New York, NY 10022 United States +1 212 337 7000
--	--	---	--	--

IMPORTANT INFORMATION

This document is classified under the FCA Handbook as being investment research (independent research). Bryan, Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

This report is prepared by Bryan, Garnier & Co Limited, registered in England Number 03034095 and its MIFID branch registered in France Number 452 605 512. Bryan, Garnier & Co Limited is authorized and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange. Registered address: Beaufort House 15 St. Botolph Street, London EC3A 7BB, United Kingdom.

This Report is provided for information purposes only and does not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. This Report is for general circulation to clients of the Firm and as such is not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

The information and opinions contained in this Report have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in this Report are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of this Report. Information may be available to the Firm and/or associated companies which are not reflected in this Report. The Firm or an associated company may have a consulting relationship with a company which is the subject of this Report.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firm's prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Disclosures specific to clients in the United Kingdom This Report has not been approved by Bryan, Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan, Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

This Report is based on information obtained from sources that Bryan, Garnier & Co Limited believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan, Garnier & Co Limited and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its

accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan, Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.